Evaluation of Anti-Xa Levels in Surgery Patients Receiving Weight-based Heparin
Deep Vein Thrombosis, Pulmonary Embolism, Venous Thromboembolism
About this trial
This is an interventional prevention trial for Deep Vein Thrombosis
Eligibility Criteria
Inclusion Criteria:
- Patients undergoing surgical procedures
- Initiation of a heparin infusion at a rate of 500 units/hour intraoperatively or postoperatively
Exclusion Criteria:
- Age <18 years old
- Pregnant
- Incarcerated
- Mentally disabled
Sites / Locations
- University of Utah
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
Standard heparin dose
Real time heparin dose adjustment
The investigators will identify surgical patients placed on fixed dose heparin infusions at their attending surgeon's discretion-the proposed research will not dictate the initiation of the heparin drip intraoperatively. However, the investigators will identify patients already on heparin, evaluate steady state heparin anti-Xa levels and adjust patient's dose if necessary based on steady state anti-Xa levels. Eligible patients will be started on heparin fixed-dose intraoperatively and transitioned to a weight-based dose by their surgeons. Steady state anti-Xa levels will be drawn at least 6 hours after initiation of heparin infusion. Goal anti-Xa levels will be 0.1-0.35 IU/mL.
Patients with identified out of range levels will receive pharmacist-driven real time heparin dose adjustment and will receive follow-up steady state anti-Xa levels. Anti-Xa level monitoring will be discontinued when in range peak levels are obtained, when heparin infusions are discontinued at surgeon discretion, or when the patient is discharged